TME Pharma readies randomized Phase 2 glioblastoma trial protocol for NOX-A12 as licensing talks near decision stage

• TME Pharma moved into final-stage talks with two potential partners for a NOX-A12 license to fund the next glioblastoma study.
• Clinical results were already presented in a recent peer-reviewed Nature Communications publication supporting NOX-A12’s trial outcomes.
• The update points to improved survival outcomes versus standard care, without disclosing new trial readouts or additional study endpoints.
• A randomized Phase 2 protocol is ready to start in Germany, with a U.S.-cleared pathway, pending a partner selection decision.
• NOX-E36 partnering remains earlier-stage, with a recently completed method-validation study positioned to support future ophthalmology development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.